15-F2t-Isoprostane Favors an Anti-Inflammatory Phenotype in RAW 264.7 Macrophages during Endotoxin Challenge.

Abstract

Dysregulated inflammation and oxidative stress are major underlying components of several diseases. Macrophages are critical effector cells in immune responses, functioning to progress and resolve inflammation during such diseases. These mononuclear cells regulate inflammatory responses by exhibiting a range of phenotypes that evolve with the process, first promoting inflammation but then switching to a proresolving subtype to restore tissue homeostasis. Furthermore, macrophages are a primary source of isoprostanes (IsoPs), a nonenzymatic byproduct of lipid peroxidation during inflammation. As highly sensitive and specific indicators of lipid damage, IsoPs are the gold standard biomarker of oxidative stress. However, the physiological role of IsoPs during inflammation is currently not well-established. This study determined how IsoPs affect macrophage phenotype during lipopolysaccharide (LPS) challenge. RAW 264.7 macrophages (n = 7) were challenged with 5 ng/mL LPS for 8 h, followed with or without 500 nM 15-F2t-IsoP for 1 h. Macrophage phenotype was determined using metabolic, transcriptomic, and proteomic markers. Phenotypic markers assessed included ATP production; transcription of proinflammatory Nos2, Il1β, and anti-inflammatory Il10; and translation markers IL1α and IL6 (proinflammatory) with G-CSF and IL17 (anti-inflammatory). Statistical analyses included one-way ANOVA followed by Tukey’s posthoc test. Significance was set at p < 0.05. In combination with LPS, 15-F2t-IsoP increased ATP production relative to LPS-only treated cells. Additionally, gene expression of Nos2 and Il1β were decreased while Il10 was increased. Cytokine production of IL6 was decreased while IL10, G-CSF, and IL17 were increased. Collectively, these results provide evidence that 15-F2t-IsoP promotes an anti-inflammatory macrophage phenotype during LPS challenge. These data support a novel physiological role of IsoPs, where these lipid mediators may participate in healing pathways during late-stage inflammation when they are elevated. Additionally, the promotion of an anti-inflammatory macrophage phenotype may contribute to preventing or mitigating inflammation during disease. Future studies should be directed towards defining the mechanisms in which IsoPs influence macrophage phenotype, such as receptor interactions and downstream signaling pathways.